Fig. 2From: Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trialsReduction in migraine headache days and migraine headache days with acute medication, by age groupBack to article page